KR20030060771A - 국소용 마취제/아편양약물 제제 및 이들의 용도 - Google Patents

국소용 마취제/아편양약물 제제 및 이들의 용도 Download PDF

Info

Publication number
KR20030060771A
KR20030060771A KR1020027014500A KR20027014500A KR20030060771A KR 20030060771 A KR20030060771 A KR 20030060771A KR 1020027014500 A KR1020027014500 A KR 1020027014500A KR 20027014500 A KR20027014500 A KR 20027014500A KR 20030060771 A KR20030060771 A KR 20030060771A
Authority
KR
South Korea
Prior art keywords
morphine
administered
topical
pharmaceutical composition
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020027014500A
Other languages
English (en)
Korean (ko)
Inventor
파스터낙가브릴
콜레스닉코브유리
Original Assignee
메모리얼 슬로안-케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안-케터링 캔서 센터 filed Critical 메모리얼 슬로안-케터링 캔서 센터
Publication of KR20030060771A publication Critical patent/KR20030060771A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020027014500A 2000-04-28 2001-04-27 국소용 마취제/아편양약물 제제 및 이들의 용도 Ceased KR20030060771A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20043700P 2000-04-28 2000-04-28
US60/200,437 2000-04-28

Publications (1)

Publication Number Publication Date
KR20030060771A true KR20030060771A (ko) 2003-07-16

Family

ID=22741721

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027014500A Ceased KR20030060771A (ko) 2000-04-28 2001-04-27 국소용 마취제/아편양약물 제제 및 이들의 용도

Country Status (8)

Country Link
US (2) US6825203B2 (https=)
EP (1) EP1276475A2 (https=)
JP (1) JP2004512260A (https=)
KR (1) KR20030060771A (https=)
AU (1) AU2001257326A1 (https=)
CA (1) CA2407683C (https=)
IL (1) IL152473A0 (https=)
WO (1) WO2001082914A2 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100762018B1 (ko) * 1998-07-16 2007-10-04 메모리얼 슬로안-케터링 캔서 센터 오피오이드 진통제 및 엔엠디에이 길항제를 함유하는 국소조성물
NZ514515A (en) 1999-03-23 2003-11-28 Global Cardiac Solutions Pty L Organ arrest, protection and preservation using a potassium channel operator and/or adenosine receptor and a local anaesthetic
DE60143671D1 (de) * 2001-06-07 2011-01-27 Sang Christine Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB0121980D0 (en) 2001-09-11 2001-10-31 Cathnet Science Holding As Expandable stent
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
US7294146B2 (en) 2001-12-03 2007-11-13 Xtent, Inc. Apparatus and methods for delivery of variable length stents
US20040186551A1 (en) 2003-01-17 2004-09-23 Xtent, Inc. Multiple independent nested stent structures and methods for their preparation and deployment
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
US7182779B2 (en) 2001-12-03 2007-02-27 Xtent, Inc. Apparatus and methods for positioning prostheses for deployment from a catheter
US7351255B2 (en) 2001-12-03 2008-04-01 Xtent, Inc. Stent delivery apparatus and method
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US20030135266A1 (en) 2001-12-03 2003-07-17 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US7309350B2 (en) 2001-12-03 2007-12-18 Xtent, Inc. Apparatus and methods for deployment of vascular prostheses
US7147656B2 (en) 2001-12-03 2006-12-12 Xtent, Inc. Apparatus and methods for delivery of braided prostheses
PT1534313E (pt) 2002-07-30 2013-01-25 Omeros Corp Soluções e método de irrigação oftalmológica
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2551169A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
US7241308B2 (en) 2003-06-09 2007-07-10 Xtent, Inc. Stent deployment systems and methods
US7326236B2 (en) 2003-12-23 2008-02-05 Xtent, Inc. Devices and methods for controlling and indicating the length of an interventional element
US7323006B2 (en) 2004-03-30 2008-01-29 Xtent, Inc. Rapid exchange interventional devices and methods
US20050265219A1 (en) * 2004-05-11 2005-12-01 Texas Instruments Incorporated Orthogonal frequency division multiplex (OFDM) packet detect unit, method of detecting an OFDM packet and OFDM receiver employing the same
EP1595541A1 (en) * 2004-05-12 2005-11-16 Alcasynn Pharmaceuticals Gmbh Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20050288766A1 (en) 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US8317859B2 (en) 2004-06-28 2012-11-27 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
JP4849642B2 (ja) 2004-11-24 2012-01-11 ネオプロ ラブス， エルエルシー 状態を処置するための方法および組成物
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
US7695733B2 (en) 2006-02-17 2010-04-13 Zasler Nathan D Application of topical anesthetics for modulation of neurogenic tremor
EP1998716A4 (en) 2006-03-20 2010-01-20 Xtent Inc APPARATUS AND METHODS FOR ESTABLISHING RELATED PROSTHETIC SEGMENTS
AU2006345361B2 (en) 2006-05-29 2014-04-10 Hibernation Therapeutics, A Kf Llc Improved tissue maintenance
CA2692256C (en) 2006-07-25 2017-01-10 Hibernation Therapeutics Limited Trauma therapy
TW200815004A (en) * 2006-09-19 2008-04-01 Chi Mei Foundation Hospital Local anesthetic composition containing dextrorotatory morphinan derivative or pharmaceutically acceptable salts thereof
WO2008051527A2 (en) * 2006-10-23 2008-05-02 Psivida, Inc. Sustained release of agents for localized pain management
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
US20080199510A1 (en) 2007-02-20 2008-08-21 Xtent, Inc. Thermo-mechanically controlled implants and methods of use
EP2173353B1 (en) 2007-03-02 2015-05-06 Hibernation Therapeutics, a KF LLC Composition including Adenosine and Lignocaine
US8486132B2 (en) 2007-03-22 2013-07-16 J.W. Medical Systems Ltd. Devices and methods for controlling expandable prostheses during deployment
JP2010527377A (ja) 2007-05-17 2010-08-12 ネオプロ ラブス，エルエルシー ペプチドの結晶形および非結晶形
US20090036541A1 (en) * 2007-08-02 2009-02-05 Donald David Mardis Applicator and chemical combination for better topical anesthesia
US8575190B2 (en) * 2007-11-14 2013-11-05 Mitsubishi Gas Chemical Company, Inc. Method of preventing or ameliorating psoriasis using pyrroloquinoline quinone compounds
US9101503B2 (en) 2008-03-06 2015-08-11 J.W. Medical Systems Ltd. Apparatus having variable strut length and methods of use
GB0808751D0 (en) * 2008-05-14 2008-06-18 Serentis Ltd Topical compositions of opioid compound for use in wound healing
AU2009296415B2 (en) 2008-09-25 2015-11-19 Advanced Bifurcation Systems Inc. Partially crimped stent
US12324756B2 (en) 2008-09-25 2025-06-10 Advanced Bifurcation Systems Inc. System and methods for treating a bifurcation
US12076258B2 (en) 2008-09-25 2024-09-03 Advanced Bifurcation Systems Inc. Selective stent crimping
US8821562B2 (en) 2008-09-25 2014-09-02 Advanced Bifurcation Systems, Inc. Partially crimped stent
US11298252B2 (en) 2008-09-25 2022-04-12 Advanced Bifurcation Systems Inc. Stent alignment during treatment of a bifurcation
US8769796B2 (en) 2008-09-25 2014-07-08 Advanced Bifurcation Systems, Inc. Selective stent crimping
CN103068345B (zh) 2010-03-24 2015-10-14 高级分支系统股份有限公司 在对分叉部进行处理过程中的支架对准
EP2549958A4 (en) 2010-03-24 2016-09-14 Advanced Bifurcation Systems Inc METHODS AND SYSTEMS FOR TREATING BIFURCATION WITH IMPLANTATION OF PROVISIONAL VASCULAR STENT OF LATERAL RAMIFICATION
EP2549952A4 (en) 2010-03-24 2017-01-04 Advanced Bifurcation Systems, Inc. System and methods for treating a bifurcation
WO2012109365A1 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. System and methods for treating a bifurcation with a fully crimped stent
CA2826760A1 (en) 2011-02-08 2012-08-16 Advanced Bifurcation Systems, Inc. Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use
SMT202100228T1 (it) 2011-04-29 2021-05-07 Moberg Pharma Ab Composizioni farmaceutiche comprendenti un anestetico locale come bupivacaina per somministrazione locale alla bocca o alla gola
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
BR112013028802B1 (pt) 2011-05-10 2021-10-26 Itochu Chemical Frontier Corporation Curativo adesivo não-aquoso
ES3034911T3 (en) 2011-05-10 2025-08-26 Itochu Chemical Frontier Corp Non-aqueous patch
LT2823815T (lt) 2011-09-27 2018-08-27 Itochu Chemical Frontier Corporation Nevandeninis pleistras
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
BR112016000809A2 (pt) 2013-07-17 2017-08-22 Hibernation Therapeuitics A Kf Llc Método para tratar infecção, sepsia e lesão
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
HUE070412T2 (hu) 2016-04-12 2025-06-28 Tonix Pharma Ltd Magnézium tartalmú oxitocin készítmények és alkamazási eljárásaik
US11160799B2 (en) 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
CN114373519A (zh) * 2021-12-31 2022-04-19 苏州佩德生物医药有限公司 一种trpv3抑制剂的虚拟筛选方法、药物先导化合物及应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446140A (en) 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
DE4223004A1 (de) 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
WO1994014427A2 (en) 1992-12-23 1994-07-07 Zymogenetics, Inc. Use of skyrin and analogues for the treatment of diabetes mellitus and process for their preparation
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5635204A (en) 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
US5589480A (en) 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
KR960019204A (ko) 1994-11-01 1996-06-17 이헌조 씨디-롬, 플로피디스크겸용 드라이브 및 구동방법
US5866143A (en) 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
JP2001501221A (ja) 1996-09-30 2001-01-30 ヘキスト・マリオン・ルセル・インコーポレイテツド Ｎｍｄａ（ｎ―メチル―ｄ―アスパラギン酸）アンタゴニスト
ES2174337T3 (es) 1996-12-16 2002-11-01 Alcon Lab Inc Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
DK1003494T3 (da) 1997-01-22 2007-07-16 Cornell Res Foundation Inc (d)-metadon, et ikke-opioidt analgetikum
US5834480A (en) 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders
KR100762018B1 (ko) 1998-07-16 2007-10-04 메모리얼 슬로안-케터링 캔서 센터 오피오이드 진통제 및 엔엠디에이 길항제를 함유하는 국소조성물
JP2000169378A (ja) 1998-12-10 2000-06-20 Taisho Pharmaceut Co Ltd 咽頭疾患用組成物
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds

Also Published As

Publication number Publication date
JP2004512260A (ja) 2004-04-22
AU2001257326A1 (en) 2001-11-12
IL152473A0 (en) 2003-05-29
EP1276475A2 (en) 2003-01-22
US20020004484A1 (en) 2002-01-10
WO2001082914A2 (en) 2001-11-08
CA2407683C (en) 2010-04-13
US6790855B2 (en) 2004-09-14
US6825203B2 (en) 2004-11-30
WO2001082914A3 (en) 2002-08-01
CA2407683A1 (en) 2001-11-08
US20020052319A1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
KR20030060771A (ko) 국소용 마취제/아편양약물 제제 및 이들의 용도
EP0897726B1 (en) Antipruritic agent
JP5863650B2 (ja) 疼痛を処置するための方法
CA2336902C (en) Topical compositions comprising an opioid analgesic and an nmda antagonist
JP2003514013A (ja) 医薬組成物
HUT70160A (en) Process for producing des-tyr dynorphin analogues
AU2019207531B2 (en) Peptides and uses thereof
KR20020016832A (ko) 모르핀 글루코네이트로 이루어진 조성물 및 방법
WO2003009805A2 (en) Analgesic methods using endothelin receptor ligands
CN102711759B (zh) 胆道疾病的治疗或预防药
JPH10511077A (ja) Ｎ末端基で切断されたダイノルフィン類似体を用いた鎮痛方法
JP2001506652A (ja) 眼の痛みを治療するためのκオピオイド・アゴニストの局所使用
US7820688B2 (en) Topical anesthetic/opioid formulations and uses thereof
KR20010021851A (ko) 항통각과민성 아편제의 분무 제형 및 이를 사용하여국소적 통각과민증 및 이에 수반되는 소양증을 치료하는방법
JP2004529959A (ja) 鎮痛剤組成物と手法
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
US20040204443A1 (en) Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives
CA Progress in the potential use of enkephalin analogs
AU2018375087B2 (en) Novel analgesic pharmaceutical formulations and uses thereof
EP1702627A1 (en) Analgesic combination of sodium channel blockers with opioid antagonists
JP2004508274A (ja) 薬物中毒の治療方法
WO2022076815A1 (en) Compositions for inducing urinary voiding and defecation
Irving New trends in opioid analgesics
JPH07503968A (ja) ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20021028

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060426

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070425

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070921

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081201

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090601

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090723

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20081201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20070921

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20070425

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I